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Abstract
INTRODUCTION: Thrombolytic treatment with recombinant tissue plasminogen activator (rtPA) is
approved by the FDA and national institute of neurological disorders for use within 3 hours as standard
therapeutic care after the onset of thrombolytic stroke. Therefore all patients who present later than 3 hours
and those with an unknown time window are currently excluded from this treatment option. Thus only a small
percentage of patients can benefit. It is essential to assess the safety and efficacy of tissue plasminogen
activator, alteplase, when administered after the 3 hour onset for acute ischemic stroke patients to determine
the increase in the incidence of intracerebral hemorrhage.
METHODS: The focus of this study is to review the current literature for the last 10 years on all studies
pertaining to the safety and efficacy of tissue plasminogen activator “Alteplase” for thrombolytic stroke
patients given beyond the 3 hour standard therapeutic care window. An extensive online article search via
Ovid, Pubmed, and Up-to-date was performed as well as a review of articles from the years 1999-2009. Five
articles were assessed along with several complimentary articles for use of thrombolysis treatment within and
beyond the 3 hour time window after stroke onset.
RESULTS: A total of 5 articles; two controlled randomized trials, one prospective cohort studies, one parallel
group trial, and one open label nonrandomized trial, qualified for this systematic review. Two studies indicate
that Alteplase remains safe and improves clinical outcomes in patient with acute ischemic stroke. Another
study concluded patient selection was more important than time of treatment for good outcome, a further
study indicated that alteplase was non-significantly associated with lower infract growth and significantly
associated with increased reperfusion in patients who had mismatch of diffusion weighted MRI vs. Perfusion
weighted MRI, and the last study concluded that patients with large baseline of diffusion weighted MRI lesion
volume who received early reperfusion appear to be at greater risk of symptomatic intracerebral hemorrhage
after tPA therapy.
CONCLUSION: Based on this literature review, the use of intravenous thrombolysis alteplase improves
functional outcomes at three months if given within three hours of the standard therapeutic window, however,
alteplase can be given at 3 to 4.5 hours after ischemic stroke onset which will lead to moderate improvement,
but it will increase the incidence of symptomatic intracerebral hemorrhage. In the last ten years several
randomized trials have been published and studied on the use of thrombolysis for acute ischemic stroke
beyond the three hour window, but there not enough studies to answer several questions like: which type of
patients are most likely to be harmed, how accurate and precise is the benefit in these patients, what is the
maximum dosage that can used in ischemic stroke patients after the three hour window without any harm to
the patient? Additional randomized trials on this treatment are needed to improve the safety and efficacy of
intravenous thrombolysis alteplase.
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Abstract   
INTRODUCTION: Thrombolytic treatment with recombinant tissue plasminogen activator (rtPA) is 
approved by the FDA and national institute of neurological disorders for use within 3 hours as standard 
therapeutic care after the onset of thrombolytic stroke. Therefore all patients who present later than 3 
hours and those with an unknown time window are currently excluded from this treatment option. Thus 
only a small percentage of patients can benefit. It is essential to assess the safety and efficacy of tissue 
plasminogen activator, alteplase, when administered after the 3 hour onset for acute ischemic stroke 
patients to determine the increase in the incidence of intracerebral hemorrhage.   
   
METHODS: The focus of this study is to review the current literature for the last 10 years on all studies 
pertaining to the safety and efficacy of tissue plasminogen activator “Alteplase” for thrombolytic stroke 
patients given beyond the 3 hour standard therapeutic care window. An extensive online article search 
via Ovid, Pubmed, and Up-to-date was performed as well as a review of articles from the years 1999-
2009. Five articles were assessed along with several complimentary articles for use of thrombolysis 
treatment within and beyond the 3 hour time window after stroke onset.  
 
RESULTS: A total of 5 articles; two controlled randomized trials, one prospective cohort studies, one 
parallel group trial, and one open label nonrandomized trial, qualified for this systematic review. Two 
studies indicate that Alteplase remains safe and improves clinical outcomes in patient with acute 
ischemic stroke. Another study concluded patient selection was more important than time of treatment 
for good outcome, a further study indicated that alteplase was non-significantly associated with lower 
infract growth and significantly associated with increased reperfusion in patients who had mismatch of 
diffusion weighted MRI vs. Perfusion weighted MRI, and the last study concluded that patients with 
large baseline of diffusion weighted MRI lesion volume who received early reperfusion appear to be at 
greater risk of symptomatic intracerebral hemorrhage after tPA therapy.   
 
CONCLUSION: Based on this literature review, the use of intravenous thrombolysis alteplase 
improves functional outcomes at three months if given within three hours of the standard therapeutic 
window, however, alteplase can be given at 3 to 4.5 hours after ischemic stroke onset which will lead to 
moderate improvement, but it will increase the incidence of symptomatic intracerebral hemorrhage. In 
the last ten years several randomized trials have been published and studied on the use of thrombolysis 
for acute ischemic stroke beyond the three hour window, but there not enough studies to answer several 
questions like: which type of patients are most likely to be harmed, how accurate and precise is the 
benefit in these patients, what is the maximum dosage that can used in ischemic stroke patients after the 
three hour window without any harm to the patient? Additional randomized trials on this treatment are 
needed to improve the safety and efficacy of intravenous thrombolysis alteplase.     
 
KEYWORDS:  Intracerebral hemorrhage, acute stroke, thrombolytic therapy, ischemic stroke, time 
factors, tissue plasminogen activator, magnetic resonance imaging, diffusion-weighted and perfusion-
weighted imaging, hemorrhage, reperfusion therapy.   
 
  3 
 
Acknowledgements 
 
 
 To Jeff Rostai, my biggest supporter and the worlds most amazing brother.  Thank you very 
much for your help and support during these difficult years.  
 
 To Dr. Pedmonte & Professor Ortiz:  Thank you for helping me with this project and 
encouraging all of us to see the bigger picture in the end…for the end is worth it. Thank you for all your 
encouragement and support during the didactic and clinical year and for believing in me.  
 
 To Dr. James Martin:  Thank you for exposing me to so much so fast.  It was truly a great 
rotation and one I will always look back on. I am truly a better Physician Assistant because of your love 
and support.  
 
 To My Family:  Thank you for all your support and encouragement along the way.  I could not 
ask for a more caring and blessed family. 
 
 
  4 
 
Table of Contents 
 
 
Statement of Approval ……….……..………………………………...………………….. 1 
 
Biography …..….…………….…………………………………………………………… 2 
 
Abstract ….……..…………..…………………………………………………………...... 3 
 
Acknowledgements …...………………...………………………………………………… 4 
 
Table of Contents …...……………..……………………………………………………… 5 
 
List of Tables ……………………………………………………………………………… 6 
 
List of Abbreviations.……....…………….………………………………………………... 7 
Introduction and Background…………….…………………………………………………8 
  
Methods ……………..………………………..…………………………………………… 11 
 
Results ….………………..……………………………..…………………………………. 12 
 
Review of Literature……………………………………………………………...................13  
 
Discussion……………………………....………………………………………………….. 30   
 
Conclusion…………………………………………………………………………………. 33    
 
Tables ………....…….…………………………………………………………………….. 34 
 
References …………. …...………………………………………………………………… 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  5 
 
 
 
List of Tables 
 
Table I:  Summary of Review of Literature Articles 
   
Table II: Proportion of patients in the 3–4.5-h and within 3-h cohorts according to time from stroke 
onset to treatment.  
 
Table III: Main and additional outcomes for patients treated between 3 h and 4.5 h compared with those 
treated within 3 h.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  6 
 
 
  7 
 
List of Abbreviations 
 
 
NINDS……………………………………………... National Institute of Neurological Disorders 
 
tPA………………………………………………….......................Tissue Plasminogen Activator 
  
DIC………………………………………………………Disseminated Intravascular Coagulation 
 
DWI…………………………………………………………………….Diffusion-Weighted MRI 
 
PWI..........................................................................................................Perfusion-Weighted MRI 
 
ICH……………………………………………………………………..Intracerebral Hemorrhage  
 
NIHSSS…………………………………………National Institutes of Health Stroke Scale Score 
 
SICH...……………………………………………………Symptomatic Intracerebral Hemorrhage  
 
SITS...........................................................................Safe Implementation of Treatments in Stroke 
 
ISTR………………………………………………….International Stroke Thrombolysis Registry 
 
mRS………………………………………………………………………..Modified Rankin Scale 
 
EMEA…………………………………………………..European Medicines Evaluation Agency  
 
TIA……………………………………………………………………..Transient Ischemic Attack 
  
 
 
 
 
 
 
 
 
 
 
 
 
  8 
The Relationship Between Recombinant Tissue Plasminogen Activator (rtPA) 
Beyond 3 Hours Therapeutic Window And The Incidence of Intracerebral 
Hemorrhage In Acute Ischemic Stroke Patients. 
   
Introduction 
 
 A stroke is characterized by the sudden loss of blood circulation to an area of the 
brain, resulting in a corresponding loss of neurologic function. An ischemic stroke is 
caused by a block in a blood vessel that stops the flow of blood and deprives the 
surrounding brain tissue of oxygen. In the absence of oxygen, the brain cells in the 
immediate area begin to die and release toxic chemicals that damage brain tissue in the 
surrounding area. A stroke can occur when the blood supply to a part of the brain is 
interrupted or severely reduced, depriving brain tissue of oxygen and within a few 
minutes, brain cells begin to die. A stroke is a medical emergency, and a rapid treatment 
is crucial. If a stroke is treated early it can minimize damage to the brain and potential 
stroke complications. There are two types of stroke Ischemic stroke and Hemorrhagic 
stroke.   
Ischemic stroke: 
Ischemic stroke is the most common occurring for about 80 percent of all strokes.1 They 
occur when the arteries to the brain are narrowed or blocked, causing severely reduced 
blood flow or ischemia. The most common types of ischemic strokes are: 
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1. Thrombotic stroke- This type of stroke occurs when a blood clot (thrombus) 
forms in one of the arteries that supply blood to the brain. A blood clot usually 
forms in areas damaged by atherosclerosis — a disease in which the arteries are 
clogged by fatty deposits or plaques.1 
2. Embolic stroke- An embolic stroke occurs when a blood clot or other particle 
forms in a blood vessel usually from the heart, or from the lower extremities and 
travels the bloodstream to block the smaller arteries in the brain. This type of 
blood clot is called an embolus. It is mostly caused by an irregular heart beat 
which leads to poor blood perfusion and allows the clot to form.1 
Hemorrhagic stroke:  
 A hemorrhagic stroke occurs when a blood vessel in the brain leaks or ruptures. This 
can result from different conditions that have an effect on the blood vessels, including 
uncontrolled high blood pressure or hypertension and weak spots in the blood vessel 
walls known as aneurysms. There are two main types of hemorrhagic stroke1:  
Intracerebral hemorrhage- This type of stroke is occurs when a blood vessel in the 
brain bursts and spills blood into the surrounding tissue, and damaging the cells.  High 
blood pressure is the most common cause of hemorrhagic stroke. Constant high blood 
pressure can cause these small arteries in the brain to become delicate and susceptible to 
rupture.  
Subarachnoid hemorrhage- In this type of stroke bleeding starts mainly in the large 
artery and spills blood into the area between the subarachnoid space and skull. It is often 
caused by a sudden and severe "thunderclap" headache or by the rupture of an aneurysm, 
which may be due to increased age or genetically inherited. The management and 
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treatment of patients who have an ischemic stroke involves several critical steps like: 
Ensure the medical stability of the patient, reverse any conditions that contribute to the 
symptoms of stroke, screen for potential contraindications to thrombolysis and timely 
restore blood flow using thrombolytic.   
 Treatment with medications for ischemic stroke involves dissolving the clots with drugs 
which must be administered within 3 hours of the onset of the symptoms. These 
treatments not only improve the chances of survival, but also reduce complications 
resulting from the stroke.1  
Aspirin- Aspirin is the best-proven immediate treatment after a stroke to reduce the 
likelihood of having another stroke. In the event of a hemorrhagic stroke, taking aspirin 
could worsen the bleeding. Other blood-thinning drugs, such as warfarin (Coumadin) and 
heparin also may be given, but they aren't as commonly used as aspirin.1 
Tissue plasminogen activator- Some people who are having a stroke can benefit from 
an injection of tissue plasminogen activator “rtPA”.  TPA is a potent clot dissolving drug 
that helps some people who have had stroke to recover more fully.1 However, the drug 
can only be given to patients within a three-hour window of the stroke occurring, and it 
can only be given in situations in which doctors are certain that giving TPA will not 
worsen the bleeding in the brain. TPA is contraindicated in people who are having a 
hemorrhagic stroke. Intravenous thrombolysis with Alteplase is the only approved 
treatment for acute ischemic stroke. It is currently approved by the FDA and by the 
European medicine evaluation committee in for acute ischemic stroke. The use of tissue 
plasminogen activator is approved up to 3 hours after the onset of ischemic stroke 
symptoms, but despite the overall positive outcome, a significant risk of thrombolysis 
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related intracranial hemorrhage still remains. The efficacy and safety when administered 
more than 3 hours after the onset of symptoms has not been established. The objective of 
this research paper is to determine whether a patient who presents with ischemic stroke 
after 3 hours or those with an unknown time window, can still benefit from intravenous 
thrombolysis Alteplase without increase in the risk of intracerebral hemorrhage.21     
 
Materials and Methods 
 
A comprehensive literature search was compiled using the keywords: 
Intracerebral hemorrhage, acute stroke, thrombolytic therapy, ischemic stroke, time 
factors, tissue plasminogen activator, magnetic resonance imaging, diffusion-weighted 
and perfusion-weighted imaging, hemorrhage, and perfusion therapy.  Literature from 
1999 to the present was reviewed and analyzed for importance in answering the clinical 
question. The focus of study was to determine if thrombolytic therapy after three hours 
would increase the risk of early symptomatic intracerebral hemorrhage, death and other 
adverse affects. Each article was reviewed and graded on the following criteria: 
randomization, type of studies, sample size, adverse affects, reperfusion-weighted MRI, 
diffusion-weighted MRI, magnetic resonance imaging, control group, age, and duration 
of treatment and time window .These results were then compiled and analyzed.  The 
inclusion criteria were all pertinent English language articles or data, published after 
1999 that aided in explaining the effects of the intravenous thrombolytic, alteplase, 
beyond the 3 hour window for acute ischemic stroke patients.  Exclusion criteria included 
articles published before 1999, review studies, observational studies of thrombolytics, 
articles that used Human Tissue Urokinase type activator instead of rtPA. Also excluded 
were patient who had severe intracerebral hemorrhages or early ischemic changes in 
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more than one third of the middle cerebral artery on baseline CT, and patients older than 
80 years of age.  
Results 
A total of 5 articles; two controlled randomized trials, one prospective cohort 
study, one parallel group trial and one open label nonrandomized trial, qualified for this 
systematic review. Two studies indicate that alteplase remains safe and improves clinical 
outcomes in patient with acute ischemic stroke. Another study concluded patient 
selection was more important than time of treatment for a good outcome, a further study 
indicated that alteplase was non-significantly associated with lower infract growth and 
significantly associated with increased reperfusion in patients who had a mismatch of 
diffusion weighted MRI versus perfusion weighted MRI, and the last study concluded 
that patients with a large baseline of diffusion weighted MRI lesion volume who received 
early reperfusion, appeared to be at greater risk of symptomatic intracerebral hemorrhage 
after tPA therapy.  
Hacke, and Kaste examined the current efficacy and safety of alteplase 
administered between 3 and 4.5 hours after the onset of a stroke because its efficacy and 
safety when administered more than 3 hours after the onset of symptoms have not been 
established.     The Study selection was prioritized and randomly assigned patients with 
acute ischemic stroke in a 1:1 double blinded fashion to receive treatment with 
intravenous alteplase 0.9 mg per Kg of body weight or with placebo.  Patients were 
accepted into the study if they were 18 to 80 years of age, had a diagnosis of acute 
ischemic stroke and were able to receive the study drug within 3 to 4 hours after the onset 
of symptoms. The study enrolled 821 patients of which 418 was randomly assigned to 
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treatment with alteplase, thirteen people were lost due to lack of follow- up, and among 
the 403 patients that were assigned to receive placebo, ten people were lost due to lack of 
follow-up. The median for the administration of the alteplase was 3 hours and 59 
minutes. A total of 771 patients were evaluated by the means of CT and fifty patients by 
the means of MRI at baseline. Alteplase and matched placebo were reconstituted from a 
lyophilized powder in sterile water for injection. Of the total dose only 10% was 
administered as a bolus, and the remainder was given by continuous intravenous infusion 
over a period of 60 minutes.3 A cerebral computed tomographic (CT) scan was required 
before randomization to exclude patients who had an intracranial hemorrhage or major 
ischemic infraction.   
The primary end point disability at ninety days, dichotomized as a favorable 
outcome a score of ( 0-1)  on the modified Rankin scale which has a range of zero to six, 
with zero indicating no symptoms at all and six indicating death. The secondary end point 
was global outcome analysis of four neurologic and disability scores combined. The 
safety end points included death, symptomatic intracranial hemorrhage or any other 
adverse events.3For patients that were lost from the study the worst possible outcome for 
the primary end point were inputted. Those patients that were excluded from the study 
had a history of stroke and diabetes, treatment with oral anticoagulant within 24 hours, 
broken medication code, treatment with a prohibited medication, diagnosis of ischemic 
stroke, or had not signed an informed consent or had withdrawn consent. The results of 
the study showed, that more patients had a favorable outcome with Alteplase than with 
the placebo (52.4% vs. 45.2%; with odds ratio of 1.34 at 95% confidence interval [CI], 
1.02 to 1.76; P=0.04). In the global analysis the outcome was also improved with the 
  14 
alteplase group compared to the placebo group; with an odds ratio of (1.28; 95% CI, 1.00 
to 1.65; P<0.05).3 The incidence of intracranial hemorrhage was much higher with the 
alteplase group compared to the placebo group, (27.0% vs. 17.6%; P= 0.001) and for 
symptomatic intracranial hemorrhage, 2.4% vs. 0.2%; P=0.008). There was not a 
significant difference in the mortality rate between the alteplase group and the placebo 
group; (7.7% and 8.4% respectively; P=0.68).3   
More specifically in this randomized, placebo controlled study, a total of 66 
patients died, 418 patients in the alteplase group 32 patients (7.7%) and 34 patients out of 
403 patients in the placebo group (8.4%). Also there were more cases of intracranial 
hemorrhage in the alteplase group than placebo group. The incidence of symptomatic 
intracranial hemorrhage with alteplase was less than three cases per 100 patients (10 of 
418 patients [2.4%]), but the incidence was significantly higher than the incidence with 
placebo (1 of 403 patients [0.35]; odds ratio, 9.85; 95% CI, 1.26 to 77.32; P=0.008). All 
symptomatic intracranial hemorrhages occurred within the first 22 to 36 hours after 
initiation of treatment. The rate of symptomatic edema did not differ significantly 
between the study groups; 6.9% in the alteplase group and 7.2% in the placebo group.3 
Hacke, sited the 1995 study by the National Institute of Neurological Disorders and 
Stroke (NINDS) which reported that patients with acute ischemic stroke who received 
alteplase (0.9 mg per Kilogram of body weight) within 3 hours after the onset of 
symptoms were at least 30% more likely to have minimal or no disability at three months 
than those who received placebo. Also the subsequent analysis of the NINDS study and 
combined analysis of data from six randomized trials which investigated thrombolysis 
treatment for ischemic stroke in a total of 2775 patients showed a clear association 
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between treatment efficacy and the interval between the onset of symptoms and the 
administration of the thrombolytic agent. The analysis suggested that the longer time 
window, as compared with the shorter time window was not associated with higher rates 
of symptomatic intracranial hemorrhage or death. The overall rate of symptomatic 
intracranial hemorrhage in this study was increased with the alteplase group compared to 
the placebo group, but there was no significant difference in the mortality rate between 
the alteplase group and the placebo group.  
In this study the intravenous alteplase given 3 to 4.5 hours after the onset of 
ischemic stroke symptoms was associated with a significant improvement in the clinical 
outcome, with higher rate of symptomatic intracranial hemorrhage than that reported 
previously among patients treated within 3 hours. Although the finding in this study 
suggests that treatment with alteplase may be effective in patients who present 3 to 4.5 
hours after the onset of ischemic stroke symptoms, patients should be treated with 
alteplase as early as possible to maximize the benefit.    
Davis, et all experimented whether alteplase given 3-6 hour after the onset of 
stroke promotes reperfusion and attenuates infract growth in patients who have a 
mismatch in perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI).  
 The aim was to establish the effect of intravenous alteplase on the growth of lesions, 
reperfusion, and clinical outcomes in penumbral patients 3-6 hours after stroke onset.  
This study was a prospective placebo-controlled randomized trial that was done between 
2001 and 2007 in fifteen centers in Australia, New Zealand, Belgium, and the U.K, and 
included 101 patients with acute hemispheric ischemic stroke. Patients from age eighteen 
years or older had a National Institute of Health Stroke Scale Score (NIHSS) of more 
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than 4, and had a premorbid modified Rankin score (mRS) of 2 or less was included.  The 
study randomly assigned fifty two patients to the alteplase group and forty nine patients 
to the placebo group. PWI and DWI were done on each patient within 3-5 days after 
therapy, with T2-weighted MRI at around day 90.  A baseline screening with a non-
contrast CT scan was done with both groups to exclude acute hemorrhage and major 
early ischemic changes (defined as ischemia of more than one-third of the middle 
cerebral artery).4  
  Patients were treated with the next sequentially numbered treatment pack, which 
contained either alteplase (0.9 mg/Kg up to maximum of 900 mg, 10% was administered 
as bolus and the remainder over one hour) or the placebo in a double-blinded design. The 
primary endpoint was infarct growth between baselines DWI at day 90 in mismatch 
patients. And major secondary endpoints were reperfusion, good neurological outcome, 
and good functional outcome.4   This randomized trial study collected 3908 patients, who 
were screened initially with MRI, and 1224 of these patients were screened within 6 
hours and fifty two were randomly assigned to the alteplase group and forty nine patients 
to the placebo group. The principle reason for the exclusion of 2684 of the patients was 
that they were not screened within six hours, 355 patients had hemorrhage on screening 
CT, 245 had indication for alteplase treatment within three hour, 196 had NIHSS score of 
< 4, 111 had rapidly resolving symptoms, eighty five declined informed consent, eighty 
seven had other diagnosis, eighty six had morbidity, in thirty five patients their MRI was 
not done within six hour, and twenty four had major ischemic change.4  
The baseline variables of patients with mismatch of PWI and DWI were similar 
between alteplase and the placebo group. Of the forty two patients with mismatch who 
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received alteplase, all had assessment of clinical outcome and thirty seven had a valid 
imaging outcome, and all forty three patients who had mismatch and received placebo, 
had clinical and valid imaging outcomes. Out of eighty seven total patients with adequate 
baseline MRA scans, 62% had arterial obstruction, the ratio of geometric means between 
the alteplase and placebo group was not significant, (0.69 at 95% CI, P= 0.239). Infract 
growth was significantly lower in mismatch patients who received alteplase than in those 
who received placebo. Both the incidence of reperfusion and the median percentage of 
reperfusion were significantly higher in patients with mismatch who received alteplase 
than in the placebo group. Reperfusion was significantly associated with lower geometric 
mean infract growth, good neurological outcome, and good functional outcome for all 
patients and mismatch patients. The incidence of intracranial hemorrhage was 7.7% (95% 
CI 2.1-18.5) with alteplase and 0% with placebo group.  The mortality rate did not differ 
significantly when the alteplase group was compared to the placebo group for all 
patients.4  
This study concludes that the primary outcome, lower infract growth with 
alteplase in mismatch patients, was negative when analyzed by the ratio of geometric 
means.  However, other growth measures, the relative growth and proportion of patients 
with no infract growth supported the hypothesis of attenuated infract growth with 
alteplase beyond 3 hours. Treatment with intravenous alteplase within 3-6 hours of stroke 
onset did not result in significantly lower infract growth across all measures and 
significant increase in reperfusion. Reperfusion was increased by alteplase 3-6 hours after 
the onset of ischemic stroke and was strongly associated with infract growth attenuation, 
good neurological outcome and good functional outcome. In this study the sample size 
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was too small to assess the effects of alteplase on clinical outcome in patients who had a 
mismatch of DWI and PWI. The study also did not plan to use mismatch in the selection 
of patients, because rapid online detection of mismatch was not feasible and they were 
eager to include a proportion of patients without mismatch for an exploratory analysis. 
 The strength of the study included the effective randomization, good matching of 
key baseline prognostic determinants, and inter-observer agreement of imaging 
parameters. The weakness of the study lay in low power to test some hypotheses like 
primary endpoint of growth attenuation. This study provides further evidence that the 
time window for thrombolysis treatment might be extended beyond 3 hours in some 
patients. Alteplase was non-significantly associated with lower infract growth and 
significantly associated with increased reperfusion in patients who had mismatch, and 
because reperfusion was associated with improved clinical outcomes, a phase III trial 
beyond the 3 hours after treatment with clinical endpoints, needs to be further studied.  
 
Lansberg, enrolled a total of seventy-four patients prospectively  in an open-
labeled study of intravenous tPA administered between 3 and 6 hours after symptom 
onset and an MRI was obtained before 3 to 6 hours after tPA administration. 5 Patients 
were eligible if they had a clinical syndrome consistent with stroke, a National Institute 
of Health Stroke Scale Score (NIHSSS) of > 5 and no evidence of acute hemorrhage or 
clearly identifiable hypodensity involving the 1/3 middle cerebral artery distribution on 
pretreatment CT scan. Enrolled patients also underwent an MRI, including diffusion-
weighted MRI- (DWI) and perfusion-weighted MRI (PWI), before 3 and 6 hours after 
tPA administration of (0.9 mg/kg). Patients who developed worsening of 2 or more points 
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on the NIHSS underwent an urgent CT or MRI, and, if any degree of brain hemorrhage 
was detected on these patients, an independent Data Safety and Monitoring Board 
(DSMB) reviewed the clinical and imaging data. The DSMB classified symptomatic 
hemorrhage as either “minor” if it was associated with 2 to 3 points of worsening on the 
NIHSS within 36 hours of tPA administration or “ major” if it was associated with 4 or 
more points of worsening within 36 hours of tPA administration.  
Baseline variables that were obtained for each patient included: age, gender, 
history of cardiac disease, smoking, diabetes, stroke/TIA, hypertension, hyperlipidemia, 
serum glucose, and platelet count, systolic and diastolic at admission, NIHSSS, DWI 
lesion volume and PWI lesion volume.  Symptomatic intracerebral hemorrhage occurred 
in seven out of seventy four patients, four major and three minor and three of the four 
major SICH patients died. Of the three patients with minor SICH only one died. The 
NIHSSS, DWI lesion volume, PWI lesion volume, and reperfusion status were associated 
with an increased risk of SICH (P < 0.05). In addition, the rate of reperfusion between the 
baseline and 3 to 6 hour follow-up MRI scan for early reperfusion was greater in patients 
with SICH than in those without. 
  In multivariate analysis, DWI lesion volume was the single independent baseline 
predictor of SICH (odds ratio 1.42; 95% CI 1.13 to 1.78 per 10 ml increase in DWI lesion 
volume), and, when early reperfusion status was included in the predictive model, the 
interaction between DWI lesion volume and reperfusion status was the only independent 
predictor of SICH (odds ratio 1.77; 95% CI 1.25 to 2.50 per 10 ml increase in DWI lesion 
volume).  
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Patients with major SICH typically had baseline DWI volume > 90 ml and, both 
major and minor hemorrhages occurred almost exclusively in patients who experienced 
early reperfusion. Only one of the baseline CT scans of patients with SICH showed 
evidence of clearly identifiable hypodensity involving more the 1/3 of the middle cerebral 
artery. This patient had a major hemorrhage 4 hours after tPA treatment and died the 
same day.5  
In this study patients with large baseline DWI lesion volumes who achieve early 
reperfusion appear to be at greatest risk of symptomatic intracerebral hemorrhage after 
tPA therapy. There was a significant interaction between DWI volume and early 
reperfusion, which indicates a synergistic effect, on the risk of SICH between DWI lesion 
volume and early reperfusion.  
The finding in this study also states, that DWI volume is an independent predictor 
of SICH and is in accord with previous reports that have shown that the extent of early 
infract signs on CT is a predictor of SICH because both large DWI lesions and 
widespread CT hypodensity are markers of the severe cerebral ischemia. Because the 
previous study DEFUSE, excluded patients with hypodensity involving more than 1/3 of 
the middle cerebral artery on the CT, this study was unable to assess the influence of 
major early infract signs on CT, in this study.  Little is known about the relationship 
between reperfusion and the development of SICH in patients that are treated with 
intravenous tPA. It has been postulated that, reperfusion related damage to the ischemic 
microvasculature may contribute to the risk of symptomatic intracerebral hemorrhage. 
The finding in this study supports this view as, reperfusion, particularly in patients with 
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large baseline DWI lesion volumes, was associated with increased risk of symptomatic 
intracerebral hemorrhage.2, 5   
Kohrmann performed a nonrandomized cohort study, where he assessed the 
clinical outcomes and incidence of symptomatic intracerebral hemorrhage (ICH) in 400 
consecutive patients treated with intravenous rtPA from March of 1998 to October of 
2005. Data were prospectively obtained and entered into a local database, including 
information about age, gender, time of onset of symptoms, time of treatment, modified 
Rankin scale (mRS) score at 90 days, baseline Institutes of Health Stroke Scale Score ( 
NIHSSS) at day 1 and 7, imaging data, medication use and relevant disease.6 All the 
analysis was done retrospectively using the collected data. At the institution, an algorithm 
was used whereby patients eligible for thrombolysis within 3 hours, and, if time of onset 
is unclear, MRI was used.  
Patients in this study received both MRI and CT in a random order before 
treatment was initiated. Patients were also selected on the basis of MRI findings and 
treated at the institution only if a PWI-DWI mismatch was present. No upper limit of age 
or stroke severity was applied, only patients with an apparent DWI lesion exceeding 50% 
of the middle cerebral artery were excluded form thrombolysis treatment. A total of 18 
patients were excluded from the analysis who received rtPA beyond 3 hour on the basis 
of CT findings. The remaining 382 patients were divided into three groups: CT-based 
treatment within three hours (n=209); MRI-based treatment within 3 hour (n=103); and 
MRI-based treatment beyond the three hour window (n=70).   
Baseline stroke severity was very similar in all three subgroups (median 
NIHSSS=13). Patients in group three (MRI > 3 h) had a similar 90 day outcome to those 
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in the other two groups (48% were independent in the CT < 3 h group, 51 % in the MRI < 
3 h group, and 56% in group three), but without an increased risk for symptomatic ICH 
(9%, 1%, 6%) or mortality (21%, 13%, 11%). MRI- selected patients overall, had a 
significantly lower risk than CT-selected patients for symptomatic ICH (3% vs. 9%; 
P=0.013) and mortality (12% vs. 21%; P=0.021).  
Time to treatment did not affect outcomes. Also, incidence of ICH was 
significantly lower in patients treated according to MRI findings, than in those treated 
according to CT finding. In multivariate regression analysis this favorable response for 
MRI-based treatment was shown to be independent of the other factors that were 
examined. Also, increasing age and the severity of stroke were strong predictors for a 
worse outcome in all analyses. Symptomatic ICH, strongly predicted worse functional 
recovery. 75% of patients with symptomatic ICH died within the first 90 days and 
overall, patients who received treatment based on MRI findings had a significantly lower 
mortality rate than those treated on the basis of CT findings.6   
  The data from this study concludes that beyond three hours and maybe even 
within three hours, patient selection is more important than time in treatment for a good 
outcome. Furthermore, MRI-based thrombolysis, in spite of the time window, shows an 
improved safety profile while being at least as effective as standard CT-based treatment 
within 3 hours.2  
 Wahlgren, experimented outcomes in patients treated between 3 hour and 4.5 
hour versus those patients treated within 3 hours, who were recorded in the Safe 
Implementation of Treatments in Stroke (SITS), through a prospective internet-based 
audit of the International Stroke Thrombolysis Registry (ISTR). This study included 
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patients presenting with ischemic stroke that were given intravenous alteplase between 3 
hours and 4.5 hours after symptom onset and registered in SITS-ISTR. As a comparison, 
the study considered patients treated within 3 hours and registered in SITS-ISTR. 
  
Patients received a full dose of alteplase (0.9 mg/kg with an upper limit of 90 mg) 
with continuous infusion over 60 minutes, with 10% of the total dose administered as a 
bolus. The investigators in the study documented baseline and demographic 
characteristics, stroke severity measured by score in National Institute of Health stroke 
scale (NIHSS), onset of treatment time, risk factors, medication history, admission to the 
hospital and follow up imaging scans.7 Outcome measures were symptomatic 
intracerebral hemorrhage within 24 hour associated with the National Institute of Health 
Stroke Scale [NIHSS] > 4 points deterioration and mortality (modified Rankin scale of 0-
2) at 3 months.7 The study included data for 664 patients with alteplase treatment started 
between three hours and 4.5 hours after ischemic stroke onset and for 11865 patients 
treated within three hours. In the 3-4.5 hour cohort, treatment was started at a median of 
55 minutes later after symptom onset, median age was 3 years younger, and stroke 
severity was one point lower as measured by the NIHSS score than in the 3 hour cohort 
(195 min) vs. (140 mint), P<0.0001. The median age was three years younger (65 years 
vs. 68 years), P< 0.0001. The stroke severity was lower (NIHSS score 11 vs. 12), 
P<0.0001 than in the 3 hour cohort. There were no significant differences between the  
3-4.5 hour cohort and within 3 hour cohort for any outcome of symptomatic intracerebral 
hemorrhage (2.2% vs. 1.6%), odds ratio 1.18 at 95% CI, P=0.24. mortality (12.7% vs. 
12.2%) odds ratio 1.02, P=0.72. Also at three months the study noted no significant 
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difference between the cohorts, in mortality rates or functional independence (modified 
Rankin scale score 0-2). The two cohorts did not differ significantly in any primary cause 
of death. The study recorded intracerebral hemorrhage as a primary cause of death for 
1.2% of patients treated between 3 hour and 4.5 hour and 1.1% for those treated within 3 
hour, P=0.92. Death from a cerebral infract was the most common cause of death, 
occurring in 5.0% of patients in the 3-4.5 hour cohort compared to 4.4% in the patients in 
the within 3 hour cohort.2, 7  
The results from in this study showed that the rates of symptomatic intracerebral 
hemorrhage, mortality and independence at 3 months follow- up routine clinical practice 
are similar between patients who were treated within 3-4.5 hour and for those patients 
treated within 3 hour after ischemic stroke onset. This suggests that alteplase remains safe 
when given at 3-4.5 hour after ischemic stroke, offering the opportunity for patients who 
cannot be treated within the standard 3 hour therapeutic timeframe.   
Discussion 
The primary goal of this systematic review was to identify evidence from the 
current medical literature on the use of thrombolytic therapy for acute ischemic stroke 
patients. Thrombolytic therapy is one of the most promising treatments for acute 
ischemic stroke. It can reduce disability after stroke, but can cause serious bleeding. The 
majority of the stroke that occurs is due to blockage of an artery in the brain by clot. 
Treatment with thrombolytic drugs like alteplase can restore blood flow before major 
brain damage occurs. However thrombolytic drugs can cause serious bleeding in the 
brain and can be fatal. Intravenous thrombolysis tissue plasminogen activator, alteplase, 
is currently the only therapy approved by the FDA and the European Union for acute 
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ischemic stroke. Thrombolytic therapy has now been evaluated in several randomized 
and cohort trials in acute ischemic strokes. The thrombolytic drug alteplase (rtPA) has 
been proven and licensed for use within three hours of stroke in the United States, 
Canada and recently in most European countries, however only a small percent of patient 
can benefit within the three hour therapeutic window.  
 Hacke conducted a randomized placebo-controlled study to test the safety and 
efficacy of alteplase between 3 and 4.5 hours after the onset of a stroke and he concluded 
that patients in his study benefited from the treatment with intravenous alteplase. The 
benefit of intravenous alteplase beyond the three hour treatment window was also 
discussed in 2008 by the ECASS III trial, which concluded that intravenous alteplase is 
still beneficial when given up to 4.5 hours after stroke onset, and more patients had 
favorable outcome with alteplase than placebo, (odds ratio 1.34 at 95% CI 1.02-1.76).   
In this study the rates of symptomatic intracerebral hemorrhage between the two groups 
was significant, the incidence of symptomatic intracerebral hemorrhage was higher in the 
alteplase group than placebo group. The mortality rate between the alteplase and placebo 
group was not significant, but symptomatic intracranial hemorrhage was significantly 
higher in the alteplase group than the placebo group. 1, 4, 7 
The SITS-ISTR observational study compared the outcome in patients treated with 
alteplase for acute ischemic stroke compared to the patients treated between three hours 
and 4.5 hours and patients treated within three hours had similar rates of independence, 
symptomatic intracerebral hemorrhage and mortality rate. In contrast to these recent 
studies, earlier randomized trials of intravenous thrombolysis did not show a clear benefit 
for patients treated more than three hours after the onset of ischemic stroke; however, 
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these earlier trials had the treatment time window of up to six hours and only a small 
numbers, of patients was treated between three and 4.5 hours. Data from the SITS-ISTR 
centers show that only a small proportion of all treated patients receive thrombolysis 
within 3-4.5 hours timeframe; for most patients seventy four percent, treatment started 
within three hours and the remaining twenty two percent of patients in the registry failed 
to satisfy other selection criteria of the present labeled use of alteplase. No data are 
available within SITS-ISTR for the reasons for treatment outside the three hours limit. 
One reason could be that clinicians decide not to withhold treatment if a patient has been 
prepared and informed about thrombolysis within three hours, but more than three hours 
can elapse because of unforeseeable delays in the pre evaluation phase before treatment 
can be started.  Another reason might be that some clinicians base their decision to begin 
treatment up to 4.5 hours after stroke onset on the significant benefit reported in the meta-
analysis of all available data. One of the limitations of this cohort study and analysis for 
the outcome data in the 3-4.5 hours is the observational design. In large, multinational, 
multicenter registry studies aimed at collecting data indicative of routine clinical practice, 
perceptual and technical differences between centers are possibility that could have 
affected the assessment of intracerebral hemorrhage. Also the potential bias of patients’ 
selection for treatment beyond the three hours time frame is another consideration.    
According to Wahlgren, Hack, and Kohrmann the results showed, the odds of 
favorable outcome significantly decreased as the interval from stroke onset to start of 
alteplase treatment increased. The results from this study concludes that the earlier the 
intravenous alteplase treatment is initiated after the onset of ischemic stroke, the more 
beneficial the outcome. Also the study found that the treatment time window of 
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intravenous alteplase for ischemic stroke patients can be extended to 4.5 or even five 
hours, but the odds ratio will decrease when treatment with alteplase is used beyond the 
three hour window.  The risk of symptomatic intracerebral hemorrhage was higher in the 
alteplase group compared to the placebo group.  
According to Davis, a placebo-controlled randomized trial compared whether 
alteplase given 3-6 hours after stroke onset promotes reperfusion and attenuates infract 
growth in stroke patients, and the study found no significant benefit with lower infract 
growth on the primary MRI outcome measures. The study suggested that recanalization 
was more common after tPA and was associated with less infract growth and better 
clinical outcomes.2, 7 Another study that was done in 2007 was a multicenter German 
study that used MRI screening criteria to select patients with acute ischemic stroke for the 
use of intravenous tPA treatment. The study was not randomized, but the study made 
comparisons with pooled data from other studies; NINDS, ATLANTIS, and ECASS II 
trials that experimented the use of tPA or placebo within 6 hours. The results from the 
alteplase group were (odds ratio 1.65, at 95% CI 1.0-2.75) and the results from the 
placebo group were (odds ratio 1.78 at 95% CI 1.07-2.96) from three hours to six hours, 
and there was no agreement regarding the best technique to measure ischemic penumbra 
on MRI.  The results from the DEFUSE trial also suggested that reperfusion with 
intravenous tPA from three to six hour after stroke onset will result in a more favorable 
clinical outcomes in patients who have a baseline diffusion-perfusion mismatch than 
those patients who have no mismatch.2, 7  
 This review confirms that the use of thrombolytic therapy can reduce the risk of 
disability and mortality and that the treatment time window can be extended to beyond 
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the three hour window, but results indicate that the odds of favorable outcome will 
decrease as the interval from the stroke onset to start tPA treatment increase. However, 
there is not currently enough evidence to prove the safety and efficacy of intravenous 
thrombolysis in acute ischemic stroke patients beyond three hours.  
Conclusion 
 Based on this literature review, the use if intravenous thrombolysis alteplase 
improves functional outcome at three months if given within three hours of the standard 
therapeutic window. However, it would appear to be relatively safe to administer 
alteplase up to 4.5 hours after the onset of acute ischemic stroke which would lead to an 
overall improvement in three month outcome, but may increase the incidence of 
symptomatic intracerebral hemorrhage. Despite the small percentage increase in the risk, 
the use of alteplase may be justified. In the last ten years several randomized trials have 
been published and studied on the use of thrombolysis for acute ischemic stroke beyond 
the three hour window, but there are not enough studies to answer several questions like: 
which type of patients are most likely to be harmed, how accurate and precise is the 
benefit in these patients, what is the maximum dosage that can used in ischemic stroke 
patients after the three hour window without any harm to the patient?. Additional 
randomized trials on this treatment are needed to improve the safety and efficacy of 
intravenous thrombolysis alteplase and to answer the remaining questions.     
  
Author Published Study Type POP 
Size 
Treatments Studied Comparison Outcomes Validity 
(Jadad  
Score) 
Comments 
Hacke, W. 2008 Randomized  
Control Trial 
821 Intravenous Altelase (0.9 mg/kg) body 
weight 
        
          Placebo 
Symptomatic 
intracerebral 
Hemorrhage 
 
5 
 
Stephan, D. 
Geoffrey, D. 
2008 Randomized  
Control Trial 
101 Alteplase 3-6 h after stroke onset 
 
          Placebo Reperfusion & 
attenuates infract 
growth 
 
5 
 
Martin, L. 2007 Cohort, open 
Label 
74 tPA administered between 3 and 6 h after 
onset of stroke 
 
MRI vs. CT imaging 
for tPA  
Symptomatic 
intracerebral 
Hemorrhage 
 
0 
 
Martin, K. 
Eric, J.  
2006 Prospective 
Cohort 
400 Patients treated with intravenous tPA            No tPA Intracerebral 
Hemorrhage 
0  
Ahmed, N. 
Davalos, A 
2008 Cohort 664 Intravenous alteplase (0.9 mg/kg) 
between 3 h and 4.5 
tPA administered at 
3 hour 
Symptomatic 
intracerebral 
hemorrhage within 
24h 
 
0 
 
Schellinger, P. 2007 Cohort 1210 MRI-based & CT-based Thrombolytic 
Therapy in Acute Ischemic Stroke within 
and Behind the Established time Window 
 
 
No tPA 
NIHSS scores, Safety 
& efficacy 
 
0 
 
TABLE 1: Review of Matrix Articles7 
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TABLE II:  Proportion of patients in the 3–4·5-h and within 3-h cohorts according to time from stroke onset to treatment.7 
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TABLE III:  Main and additional outcomes for patients treated between 3 h and 4·5 h compared with those treated within 3 h.7 
 
 
Data are n/N (%; 95% CI), unless otherwise indicated. All patients were in full compliance with other European summary of product 
characteristics criteria (SITS-ISTR data at Nov 15, 2007). SICH= symptomatic intracerebral hemorrhage. SITS-MOST= Safe 
Implementation of Thrombolysis in Stroke Monitoring Study. ECASS= European-Australasian Acute Stroke Study. NINDS= National 
Institute of Neurological Disorders and Stroke. mRS= modified Rankin scale. 
 
Adjusted for age, sex, history of hypertension, diabetes mellitus, hyperlipidaemia, atrial fibrillation, congestive heart failure, previous stroke, 
independence before present stroke, smoking, aspirin treatment at stroke onset, baseline National Institutes of Health Stroke Scale score, 
baseline blood pressure, baseline blood glucose, bodyweight, alteplase, baseline antihypertensive therapy, and signs of current infarction on 
baseline imaging. 
 
† Odds ratios were calculated by comparing 3–4·5 h versus within 3 h cohorts. 
‡ Odds ratio not calculated since this was an additional analysis, not the main outcome.
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